Dr. Kishor Wasan and Colloidal Nanocarriers for Targeted Cancer Treatment: A Unique Delivery Strategy

SASKATOON, SK / ACCESSWIRE / October 18, 2021 / A December 2021 special commemorative edition of the journal Pharmaceuitcs will honour the remarkable contributions of retired Professor Kishor Wasan to the field of pharmaceutics.

Dr. Wasan has published over 300 abstracts and over 300 peer-reviewed articles in the fields of cancer therapy, lipoprotein-drug interactions, lipid-based drug delivery, and neglected global diseases. A fellow of the Canadian Academy of Health Sciences., Canadian Society for Pharmaceutical Sciences, and American Association of Pharmaceutical Scientists, Kishor Wasan has won a number of prestigious national and international awards for his significant influence on drug delivery. He also co-founded the Neglected Global Diseases Initiative at the University of British Columbia.

Professor Kishor Wasan is currently Chief Medical and Scientific Officer at Skymount Medical, Director of Research at iCo Therapeutics Inc. and Distinguished University Scholar and Adjunct Professor in the Department of Urologic Sciences, Faculty of Medicine at the University of British Columbia.

During his service as Dean of the College of Pharmacy and Nutrition at the University of Saskatchewan from August 2014 to June 2019. Dr. Wasan led the development of the PharmD program. In his role as Associate Dean, Research and Graduate Studies, at the Faculty of Pharmaceutical Sciences, University of British Columbia, Kishor Wasan led a research team effort toward the development of an oral formulation of amphotericin B for treating life-threatening fungal infections that successfully completed phase I clinical trials.

One of Dr. Wasan’s most significant contribution to the field of pharmaceutics has been the development of colloidal nanocarriers as a unique delivery strategy for targeted cancer treatment. Malignant cancer is one of the leading causes of death worldwide. In the most recent year for which statistics are available, there were 18.1 million newly diagnosed cases and 9.5 million documented deaths. Many different kinds of agents are used to treat cancer, but most have severe, untoward side effects. they become toxic. Cancers become multidrug resistant, with higher rates of recurrence and spread. Cancer drugs wipe out both cancerous and normal tissues. Colloidal nanoparticle dispersions now permit site-specific delivery for minimal adverse effects with great efficacy against malignancies.

Dr. Wasan has focused on chitosan-based nanoparticles for a variety of non-parenteral applications with his collaborator Dr. Ellen Wasan. This biodegradable, biocompatible polymer has chemical functional gr0ups that can be modified to achieve specific goals, giving a tremendous range of potential applications. Its positive surface charge makes it mucoadhesive and capable of releasing its drug payload in a sustained-release manner. Dr. Wasan’t work has enabled the creation of chitosan-based nanoparticles for drug delivery not only for cancer, but also for pulmonary diseases, gastrointestinal diseases, and for brain and ocular infections.

The journal Pharmaceutics will honor Dr. Kishor Wasan in the most appropriate manner possible, by soliciting papers based on original research building on his work. Dr. Wasan’s career has proven foundational to this exciting new class of therapeutics.

CONTACT:
Caroline Hunter
Web Presence, LLC
+1(786) 551-9491

SOURCE: Dr. Kishor Wasan

View source version on accesswire.com:
https://www.accesswire.com/668104/Dr-Kishor-Wasan-and-Colloidal-Nanocarriers-for-Targeted-Cancer-Treatment-A-Unique-Delivery-Strategy